Advertisement

The Role of Tumor Infiltrating Lymphocyte (TIL) Therapy in NSCLC

An expert in thoracic oncology, Adam J. Schoenfeld, MD, provides key insight into the use of cell therapy in non-small cell lung cancer after first-line treatment and highlights the potential for tumor-infiltrating lymphocyte (TIL) therapy depending on results from ongoing clinical trials.